Table. 4.

Preventions of viruses other than cytomegalovirus in solid organ transplantations

Characteristic Kidney (n=31) Liver (n=25) Heart (n=8) Lung (n=8)
Herpes zoster prevention
None 24 (77) 18 (72) 2 (25) 1 (13)
Prophylaxis 7 (23) 7 (28) 6 (75) 7 (88)
Acyclovir (oral) 0 4 (16) 6 (75) 0
Valacyclovir (oral) 2 (7) 0 0 0
Valganciclovir (oral), included in CMV prophylaxis 5 (16) 3 (12) 0 7 (88)
Duration of prophylaxis (mo) 3 (1‒6) 3 (1‒6) 1 (1‒6) 6 (3‒6)
EBV monitoring
None 25 (81) 18 (72) 7 (88) 5 (63)
qPCR monitoring 2 (7) 0 0 0
qPCR monitoring, if EBV D+/R– 3 (10) 5 (20) 1 (13) 0
qPCR monitoring, if pretransplant EBV qPCR+ 1 (3) 2 (8) 0 3 (38)
Duration of prophylaxis (mo) 12 (3‒12) 12 (6‒48) 12 12 (12‒24)
BK virus monitoring
None 3 (10) 0 0 0
qPCR monitoring 28 (90) 0 0 0
Blood 14 (45) 0 0 0
Urine 4 (13) 0 0 0
Blood+urine 10 (32) 0 0 0
Duration of qPCR monitoring (mo) 12 (3‒60) 0 0 0

Values are presented as number (%) or median (range).

CMV, cytomegalovirus; EBV, Epstein-Barr virus; qPCR, quantitative polymerase chain reaction.

Korean J Transplant 2022;36:212~220 https://doi.org/10.4285/kjt.22.0036
© Korean Journal of Transplantation